Serum periostin levels in COVID-19: Is it useful as a new biomarker?
Yükleniyor...
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wiley-Hindawi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objectives Severe disease characterised by interstitial pneumonia may develop in some cases of coronavirus disease (COVID-19). Periostin has been associated with many respiratory diseases. In this study, we aimed to investigate whether periostin could be a useful new biomarker in the follow-up and severity assessment of the disease in patients with COVID-19 pneumonia. Methods In the study, 32 patients followed up during May to July 2020 because of COVID-19 and 24 healthy controls were included. The patients were divided into two groups, namely, mild/moderate and severe, according to the severity of the disease. Serum periostin and transforming growth factor beta (TGF-beta) levels were tested using an enzyme-linked immunosorbent assay (ELISA) method using commercially available ELISA kits. Results It was observed that the periostin level was significantly higher in both mild/moderate cases and severe cases compared with the control group at first presentation. However, TGF-beta levels at first presentation were similar between the groups. Conclusions The current manuscript may be the first one performing periostin ELISA on COVID serum, and we believe that periostin can be used as a new biomarker.
Açıklama
Anahtar Kelimeler
Protein
Kaynak
International Journal of Clinical Practice
WoS Q Değeri
Q2
Scopus Q Değeri
Q1
Cilt
75
Sayı
11
